We propose to develop a novel acoustically activated microbubble gene delivery vehicle for treatment of experimental inflammatory bowel disease. Microbubble ultrasound contrast agents composed of a cationic lipid shell are targeted to the adhesion molecule MAdCAM-1 by a monoclonal antibody immobilized to the surface of the agent. Plasmid DNA is coupled to the cationic surface of the agent via electrostatic interaction. Microbubbles are administered intravenously and accumulate at sites of intravascular MAdCAM-1 expression, corresponding to inflammatory foci. DNA is released from the agents at the target site by ultrasound-mediated microbubble destruction using a clinical ultrasound scanner. This method has shown efficacy for transfecting reporter genes to perivascular tissue in mice and rats. This strategy offers a safe, non-viral, non-invasive method of delivering genetic material in vivo. Selectivity is accomplished by targeting the agents to a molecular marker of inflammation, and ultrasound-mediated microbubble destruction is required for release of DNA from the agent surface. The stability of these gene delivery vehicles will be examined to assess the feasibility for commercial scale production of a research-grade tool for gene delivery. The ability of these agents to selectively transfect inflamed bowel will be examined using a luciferase reporter gene and bioluminescence imaging in a mouse model of inflammatory bowel disease. This project will result in the development of a novel and efficient gene delivery tool for pre-clinical research, which can eliminate the need for problematic viral vectors and invasive electroporation techniques. Additionally, this work has the potential to translate into a clinically viable method of treatment for inflammatory bowel disease. Gene therapy offers a treatment modality for Crohn's disease, for which only symptomatic treatment is currently available. Ultrasound-mediated microbubble gene delivery is a safe, non-viral, non-invasive and high- efficiency method of transfection. The development of targeted ultrasound-activated microbubble gene delivery vehicles presents a novel and effective method of accomplishing gene transfer in pre-clinical research. This technique will offer an alternative to viral and invasive electroporation transfection techniques, and offers a potential mode for accomplishing gene delivery in a clinical setting using existing ultrasound equipment. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK079406-01
Application #
7326481
Study Section
Special Emphasis Panel (ZRG1-BST-Z (10))
Program Officer
Densmore, Christine L
Project Start
2007-09-01
Project End
2008-07-31
Budget Start
2007-09-01
Budget End
2008-07-31
Support Year
1
Fiscal Year
2007
Total Cost
$99,867
Indirect Cost
Name
Targeson, LLC
Department
Type
DUNS #
610945474
City
Charlottesville
State
VA
Country
United States
Zip Code
22903
Tlaxca, Jose L; Anderson, Christopher R; Klibanov, Alexander L et al. (2010) Analysis of in vitro transfection by sonoporation using cationic and neutral microbubbles. Ultrasound Med Biol 36:1907-18
Patil, Abhay V; Rychak, Joshua J; Allen, John S et al. (2009) Dual frequency method for simultaneous translation and real-time imaging of ultrasound contrast agents within large blood vessels. Ultrasound Med Biol 35:2021-30